Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results

Gilead posts second Phase 3 win for new HIV-fighting drug regimen

Gilead may soon be bringing a new cocktail of HIV drugs to market. The company said Monday that a combination of two drugs achieved non-inferiority

Aviceda’s geographic atrophy drug fails mid-stage study. Can it do better in Phase 3?

Aviceda Therapeutics is pushing forward with Phase 3 plans for its experimental eye drug despite failing a Phase 2b study in geographic atrophy. The mid-stage

Palvella unwraps Phase 2 data for rapamycin gel in rare skin disease

Palvella Therapeutics said its drug candidate for a rare skin disease that affects children has yielded positive results in a mid-stage trial. The biotech’s gel

InnoCare says Zenas-partnered drug succeeds in China study in form of lupus

InnoCare Pharma’s experimental oral BTK inhibitor, called orelabrutinib, succeeded in a mid-stage trial in systemic lupus erythematosus (SLE), the Chinese biotech said Sunday. After nearly

Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial

Kyverna Therapeutics’ CAR-T therapy succeeded in a key study in stiff person syndrome, a rare autoimmune disorder that leads to painful muscle spasms and stiffness.